WO1999018931A1 - Utilisation d'agent d'obturation a base de fibrine pour maintenir une hemostase, une lymphostase et empecher une accumulation locale de fluides biologiques - Google Patents

Utilisation d'agent d'obturation a base de fibrine pour maintenir une hemostase, une lymphostase et empecher une accumulation locale de fluides biologiques Download PDF

Info

Publication number
WO1999018931A1
WO1999018931A1 PCT/US1998/020928 US9820928W WO9918931A1 WO 1999018931 A1 WO1999018931 A1 WO 1999018931A1 US 9820928 W US9820928 W US 9820928W WO 9918931 A1 WO9918931 A1 WO 9918931A1
Authority
WO
WIPO (PCT)
Prior art keywords
fibrin sealant
wound
sealant
tissue
thrombin
Prior art date
Application number
PCT/US1998/020928
Other languages
English (en)
Inventor
William D. Spotnitz
Original Assignee
University Of Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Virginia filed Critical University Of Virginia
Priority to AU97861/98A priority Critical patent/AU9786198A/en
Publication of WO1999018931A1 publication Critical patent/WO1999018931A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/106—Fibrin; Fibrinogen

Definitions

  • Hemorrhagic complications associated with needle liver biopsy diagnostic procedures rise to a rate of about 2.2%, with a 50% rate of minor complications that may be attributed to blood accumulation on the peritoneal surface of the liver, or from intrahepatic hematoma.
  • Biopsy of other solid organs typically present similar rates of hemorrhagic complications, and are addressed the same way.
  • Plastic surgery frequently involves mobilization, or complete freeing, of a tissue flap, such as muscle tissue. Fibrin sealant may be applied to suppress bleeding and fluid accumulation at these sites. Other surgeries, such as thoracic surgery, involve muscle mobilization as well. Cardiovascular surgery commonly involves sternum cracking. Fibrin sealant may be used to inhibit blood flow and fluid accumulation in the bone marrow of patients' sternums.
  • Figure 2 is a graphic comparison of the drainage collected from axillary drains in mastectomy patients treated according to the claimed invention, and those treated according to status quo procedures.
  • This invention calls for the application of rapidly "setting", or polymerizing, fibrin sealant to wound and trauma sites in which hemostasis is advantageously maintained, to aid therapy, improve patient recovery, or avoid complications. While the application of fibrin sealant in surgical environments predates Applicants' invention, the controlled procedures established herein are believed to be the first to take advantage of the qualities and characteristics of fibrin sealant to maintain hemostasis, lymphostasis and tissue adhesion to improve patient recovery and prevent local accumulation of body fluids. The generic concept finds application in a wide variety of specific procedures. Each of these is discussed below.
  • Cumulative drainage for the first 3 postoperative days in the treatment group averaged 198 ⁇ 83 ml compared to 467 + 138 ml in the control group (P ⁇ 0.0003).
  • Day of drain removal averaged 3.9 + 1.7 for the treatment group and 6.9 ⁇ 1.2 for the control group (P ⁇ 0.0001).
  • there was a reduction in cumulative drainage over the first 3 days of 268 ml or 57 percent and there was a reduction in the number of days before drains can be removed of 3.0 days, or 43 percent.
  • the local application of Fibrin sealant significantly reduced the total drainage measured in patients undergoing MRM and enabled earlier drain removal.
  • MRM modified radical mastectomy
  • Plastic surgery frequently involves the liberation of a portion of a large muscle, particularly the latisimus dorci, as a flap. This may be either a free (mobile) flap or pedicel. At the spot of mobilization or separation, heavy bleeding may be sustained. Application of fibrin sealant directly to these points will suppress bleeding, allowing quick recovery without infection or complication.

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un agent d'obturation à base de fibrine, formé de thrombine et de fibrinogène mélangés et polymérisés de manière autocatalytique, cet agent d'obturation s'utilisant pour maintenir une hémostase, une lymphostase ou pour empêcher une accumulation locale de fluides dans des situations où une hémorragie ou une accumulation de fluides peut retarder la guérison, provoquer ou aggraver une douleur et un malaise ou présenter un risque pour la santé. L'agent d'obturation à base de fibrine s'utilise pour la fermeture de plaies dans lesquelles une bande de peau est appliquée sur les contours d'une plaie, comme dans les mammectomies; les incisions chirurgicales ou endoscopiques; la chirurgie orthopédique présentant une hémorragie importante; et la biopsie d'organes pleins. L'agent d'obturation à base de fibrine est également efficace pour la suppression d'une repousse de tumeurs excisées de manière chirurgicale. L'agent d'obturation à base de fibrine appliqué à la zone entourant une ouverture située dans un vaisseau sanguin ou lymphatique et due à un cathétérisme, est également efficace pour le maintien d'une hémostase.
PCT/US1998/020928 1997-10-10 1998-10-09 Utilisation d'agent d'obturation a base de fibrine pour maintenir une hemostase, une lymphostase et empecher une accumulation locale de fluides biologiques WO1999018931A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU97861/98A AU9786198A (en) 1997-10-10 1998-10-09 Use of fibrin sealant to maintain hemostasis, lymphostasis and prevent local accumulation of body fluids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94842697A 1997-10-10 1997-10-10
US08/948,426 1997-10-10

Publications (1)

Publication Number Publication Date
WO1999018931A1 true WO1999018931A1 (fr) 1999-04-22

Family

ID=25487826

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/020928 WO1999018931A1 (fr) 1997-10-10 1998-10-09 Utilisation d'agent d'obturation a base de fibrine pour maintenir une hemostase, une lymphostase et empecher une accumulation locale de fluides biologiques

Country Status (2)

Country Link
AU (1) AU9786198A (fr)
WO (1) WO1999018931A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596180B2 (en) 1996-04-30 2003-07-22 Medtronic, Inc. System and method for the production of autologous platelet gel
WO2003093433A2 (fr) * 2002-05-02 2003-11-13 Regents Of The University Of Minnesota Matrice biologique a base de fibrine
US6942880B1 (en) 2001-04-09 2005-09-13 Medtronic, Inc. Autologous platelet gel having beneficial geometric shapes and methods of making the same
US20100241160A1 (en) * 2007-06-11 2010-09-23 Kieran Murphy Method and kit for cyst aspiration and treatment
EP2745852A1 (fr) * 2012-12-21 2014-06-25 Thrombotargets Europe, S.L. Compositions d'agent d'étanchéité
EP2759305A1 (fr) * 2013-01-24 2014-07-30 Thrombotargets Europe, S.L. Compositions hémostatiques
US9096839B2 (en) 2006-04-26 2015-08-04 Arteriocyte Medical Systems, Inc. Compositions and methods of preparation thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318524A (en) * 1990-01-03 1994-06-07 Cryolife, Inc. Fibrin sealant delivery kit
US5631011A (en) * 1991-06-17 1997-05-20 Wadstroem; Jonas Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
US5810885A (en) * 1994-12-28 1998-09-22 Omrix Biopharm Sa Device for applying one or several fluids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318524A (en) * 1990-01-03 1994-06-07 Cryolife, Inc. Fibrin sealant delivery kit
US5631011A (en) * 1991-06-17 1997-05-20 Wadstroem; Jonas Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
US5810885A (en) * 1994-12-28 1998-09-22 Omrix Biopharm Sa Device for applying one or several fluids

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838039B2 (en) 1996-04-30 2010-11-23 Arteriocyte Medical Systems, Inc. Autologous fibrin sealant and method for making same
US7811607B2 (en) 1996-04-30 2010-10-12 Arteriocyte Medical Systems, Inc. Autologous fibrin sealant and method for making the same
US6596180B2 (en) 1996-04-30 2003-07-22 Medtronic, Inc. System and method for the production of autologous platelet gel
US6830762B2 (en) 1996-04-30 2004-12-14 Medtronic, Inc. Autologous fibrin sealant and method for making the same
US8303993B2 (en) 1996-04-30 2012-11-06 Ateriocyte Medical Systems, Inc. Methods of applying a biological composition to an individual
US6899813B2 (en) 1996-04-30 2005-05-31 Medtronic, Inc. Method for the production of a blood component composition
US6719901B2 (en) 1996-04-30 2004-04-13 Medtronic, Inc. System for the production of an autologous thrombin
US6942880B1 (en) 2001-04-09 2005-09-13 Medtronic, Inc. Autologous platelet gel having beneficial geometric shapes and methods of making the same
US7442397B2 (en) 2002-05-02 2008-10-28 Regents Of The University Of Minnesota PEGylated fibrinogen-based biomatrix
WO2003093433A2 (fr) * 2002-05-02 2003-11-13 Regents Of The University Of Minnesota Matrice biologique a base de fibrine
WO2003093433A3 (fr) * 2002-05-02 2004-07-29 Univ Minnesota Matrice biologique a base de fibrine
US9096839B2 (en) 2006-04-26 2015-08-04 Arteriocyte Medical Systems, Inc. Compositions and methods of preparation thereof
US20100241160A1 (en) * 2007-06-11 2010-09-23 Kieran Murphy Method and kit for cyst aspiration and treatment
CN104955493A (zh) * 2012-12-21 2015-09-30 斯洛柏塔盖兹欧洲有限公司 密封剂组合物
WO2014096354A1 (fr) * 2012-12-21 2014-06-26 Thrombotargets Europe, S.L. Compositions hémostatiques
EP2745852A1 (fr) * 2012-12-21 2014-06-25 Thrombotargets Europe, S.L. Compositions d'agent d'étanchéité
EP2759305A1 (fr) * 2013-01-24 2014-07-30 Thrombotargets Europe, S.L. Compositions hémostatiques
WO2014114719A1 (fr) * 2013-01-24 2014-07-31 Thrombotargets Europe, S.L. Compositions hémostatiques
CN104994869A (zh) * 2013-01-24 2015-10-21 斯洛柏塔盖兹欧洲有限公司 止血组合物
AU2014209886B2 (en) * 2013-01-24 2018-11-29 Thrombotargets Europe, S.L. Hemostatic compositions
CN104994869B (zh) * 2013-01-24 2020-07-07 斯洛柏塔盖兹欧洲有限公司 止血组合物

Also Published As

Publication number Publication date
AU9786198A (en) 1999-05-03

Similar Documents

Publication Publication Date Title
US5510102A (en) Plasma and polymer containing surgical hemostatic adhesives
Alving et al. Fibrin sealant: summary of a conference on characteristics and clinical uses
Emilia et al. Topical hemostatic agents in surgical practice
US5643596A (en) Hemostatic patch
US20170252479A1 (en) Biocompatible hemostatic product and preparation method thereof
US9950091B2 (en) Composition and method for stopping hemorrhage, infection, and accelerating healing in various types of wound or burns
US6458147B1 (en) Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
Lindsey et al. Seroma prevention using fibrin glue in a rat mastectomy model
US20070255238A1 (en) Hemostatic Polymer Useful for Rapid Blood Coagulation and Hemostasis
JP2018184418A (ja) 精製された両親媒性ペプチド組成物を用いた、外科的方法
US20020197302A1 (en) Hemostatic polymer useful for rapid blood coagulation and hemostasis
JPH07500095A (ja) 局所止血用止血組成物
EP1075288A1 (fr) Compositions comprenant des composes hemostatiques et des polymeres bioabsorbables
Maralcan et al. The use of fibrin glue in the treatment of fistula-in-ano: a prospective study
JP2002524110A (ja) 血管密封材および創傷被覆材として用いるためのｉ型コラーゲンおよびｉｉｉ型コラーゲン止血性組成物
US20020192271A1 (en) Method for causing local hemostasis and hemostatic composition for local hemostasis
Ohlow et al. Pocket related complications in 163 patients receiving anticoagulation or dual antiplatelet therapy: D-Stat Hemostat™ versus standard of care
KR101786786B1 (ko) 개선된 피브린 밀봉 방법
Mathes et al. Non-suture closure of nephrotomy
WO1999018931A1 (fr) Utilisation d'agent d'obturation a base de fibrine pour maintenir une hemostase, une lymphostase et empecher une accumulation locale de fluides biologiques
da Rosa Rezende et al. A comparison of the efficacy of autologous fibrin glue/platelet-poor plasma versus suction drainage in preventing hematoma and seroma in rhytidectomy: a randomized, double-blind, controlled study
Chen et al. The use of fibrin-based tissue adhesives for breast in reconstructive and plastic surgery
Spotnitz et al. Fibrin-based adhesives and hemostatic agents
JP2016507279A (ja) 大量出血に対する凍結乾燥したフィブリンシーラント
Giberson et al. Fibrin glue for the treatment of persistent lymphatic drainage

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA